Megna Michael R — SEC Form 4 filings
SEC reporting owner CIK 1464583. 21 Form 4 filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 21 filings on record, filed 2024-03-01 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 10 filings — 155,055 shares, $5,199,166 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 115.
- Largest priced transaction: sale of 37,255 shares @ $38.72 ($1,442,514) in Kiniksa Pharmaceuticals International, plc, filed 2025-10-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | CHIEF ACCOUNTING OFFICER | 21 | — | 13 legs · 155,055 sh · $5,199,166 | 115 |
Form 4 filings — Megna Michael R
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 279 @ $33.50 · Option exercise (M): 3,932 · Option exercise (M): 2,558 · Option exercise (M): 2,362 · Option exercise (M): 2,644 · Tax withholding (F): 5,531 @ $79.28 · +7 more | EDGAR |
| 2026-04-13 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Sale (S): 6,625 @ $46.69 | EDGAR |
| 2026-04-08 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 3,932 @ $1 · Tax withholding (F): 1,666 @ $48.94 · Option exercise (M): 3,932 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 372 @ $24.16 · Option exercise (M): 7,564 · Tax withholding (F): 3,205 @ $48.13 · Grant/award (A): 14,600 (derivative) @ $0 · Grant/award (A): 3,650 (derivative) @ $0 · Grant/award (A): 7,300 (derivative) @ $0 · +3 more | EDGAR |
| 2025-10-22 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 791 @ $15.50 · Option exercise (M): 6,195 @ $12.97 · Option exercise (M): 9,831 @ $11.10 · Option exercise (M): 9,831 @ $11.97 · Option exercise (M): 12,787 @ $10.76 · Sale (S): 37,255 @ $38.72 · +6 more | EDGAR |
| 2025-10-08 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 175 · Tax withholding (F): 85 @ $38.49 · Option exercise (M): 175 (derivative) @ $0 | EDGAR |
| 2025-09-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 2,363 · Option exercise (M): 2,557 · Option exercise (M): 3,933 · Tax withholding (F): 4,282 @ $33.49 · Option exercise (M): 774 · Tax withholding (F): 375 @ $34.28 · +9 more | EDGAR |
| 2025-08-06 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 495 @ $15.63 · Option exercise (M): 17,000 @ $15.52 · Sale (S): 17,000 @ $32.35 · Option exercise (M): 17,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 15,211 @ $15.50 · Sale (S): 15,211 @ $28.75 · Option exercise (M): 15,211 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 229 @ $8.83 · Option exercise (M): 2,998 @ $15.50 · Option exercise (M): 14,420 @ $11.97 · Sale (S): 17,647 @ $26.69 · Option exercise (M): 229 (derivative) @ $0 · Option exercise (M): 2,998 (derivative) @ $0 · +1 more | EDGAR |
| 2025-05-05 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 3,270 (derivative) @ $0 · Grant/award (A): 3,433 (derivative) @ $0 · Grant/award (A): 5,285 (derivative) @ $0 · Grant/award (A): 5,456 (derivative) @ $0 | EDGAR |
| 2025-04-09 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 3,933 · Tax withholding (F): 1,666 @ $20.28 · Option exercise (M): 3,933 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 2,557 · Option exercise (M): 2,363 · Tax withholding (F): 1,083 @ $21.77 · Tax withholding (F): 1,001 @ $21.77 · Grant/award (A): 21,150 (derivative) @ $0 · Grant/award (A): 10,575 (derivative) @ $0 · +2 more | EDGAR |
| 2025-03-19 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 469 @ $16 · Option exercise (M): 774 · Tax withholding (F): 328 @ $22.61 · Option exercise (M): 774 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 9,051 @ $11.10 · Sale (S): 9,051 @ $22.45 · Option exercise (M): 9,051 (derivative) @ $0 | EDGAR |
| 2024-12-02 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 8,637 @ $11.10 · Sale (S): 8,637 @ $22.45 · Option exercise (M): 9 @ $11.10 · Sale (S): 9 @ $22.45 · Option exercise (M): 8,637 (derivative) @ $0 · Option exercise (M): 9 (derivative) @ $0 | EDGAR |
| 2024-10-08 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 175 · Tax withholding (F): 82 @ $24.48 · Option exercise (M): 175 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 480 @ $15.65 · Option exercise (M): 6,490 · Tax withholding (F): 2,755 @ $26.74 · Option exercise (M): 775 · Tax withholding (F): 329 @ $26.74 · Grant/award (A): 9,450 (derivative) @ $0 · +4 more | EDGAR |
| 2024-04-08 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 3,932 · Tax withholding (F): 1,666 @ $17.90 · Grant/award (A): 18,900 (derivative) @ $0 · Grant/award (A): 9,450 (derivative) @ $0 · Option exercise (M): 3,932 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 2,558 · Tax withholding (F): 1,084 @ $19.70 · Option exercise (M): 2,558 (derivative) @ $0 | EDGAR |
| 2024-03-01 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Grant/award (A): 583 @ $12.35 · Option exercise (M): 5,126 @ $8.83 · Sale (S): 5,126 @ $21.79 · Option exercise (M): 5,645 @ $8.83 · Option exercise (M): 4,014 @ $13.88 · Sale (S): 9,659 @ $21.45 · +3 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1464583 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →